ClinicalTrials.gg
RecruitingNCT07142005Updated Sep 25, 2026

Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer

An observational study in Medullary Thyroid Cancer (MTC) and Cultural Adaptation, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Sep 25, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 81 studies in Carcinoma, Medullary with a site in United States — 12 open to participants now, 24 under way, 1 of them phase 3. Carcinoma, Medullary · United States.

Planned enrollment
10th of 10
40 · median 413
Started
2025
with 4 others
Observational
10 of 81
5 open now
Primary completion
2028-03
later than 12 of 22 live
Registered
75th of 81
by date
Lead sponsor
8 of 81
M.D. Anderson Cancer Center

Among the 81 studies in Carcinoma, Medullary with a site in United States, this one is the 10th largest by planned enrollment of the 10 observational ones that give a count, is one of 5 that started in 2025, is one of 10 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 75th registered.

Carcinoma, Medullary

144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.

Browse Carcinoma, Medullary studies →

Open to participants now

12 of the 81 studies in Carcinoma, Medullary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Carcinoma, Medullary with a site in United States, or all of them as a file.
02

Study summary

To find good information about medullary thyroid cancer that is easy to understand and reliable, so researchers aim to design some new educational materials to help.

Read the detailed description

Primary Objectives

  1. To co-develop a culturally-adapted educational tool for the Latino/Latina MTC population using the previously developed MTCEducate.org as a framework. (Phase 1)
  2. To test, refine, and produce a culturally adapted educational prototype and is intended to assess participants' understanding after reviewing the decision aid as part of the iterative testing and refinement process (Phase 2)

Secondary Objectives

  1. To assess the tool's acceptability post-production among a broader population of Latino(a) MTC participants and caregivers using the Ottawa Acceptability Scale (Phase 3)
  2. To disseminate the educational tool to a broader population of Latino(a)s
  3. To summarize the clinico-demographics of educational tool users
03

Conditions studied

  • Medullary Thyroid Cancer (MTC)
  • Cultural Adaptation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

MD Anderson Cancer Center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Males and females; Age: ≥18 years old
  • Identified ethnicity as "Hispanic" or "Latino/Latina"
  • Ability to read, write, and speak Spanish
  • Those who are pregnant are eligible to participate
  • Have or will face this decision, including: a. Participant/survivor - who has medullary thyroid carcinoma, as determined by a clinician or documented in Multi-Institutional Medullary Thyroid Cancer Collaborative Registry; b. Caregiver/family member - of Participant/survivor who has medullary thyroid carcinoma, as nominated by the Participant/survivor

Exclusion criteria

Exclusion Criteria:

  • Those \< age 18
  • Ethnic identity as non-Hispanic or non-Latino/a individual
  • Individuals with cognitive or psychological impairment (e.g., depression, anxiety, severe mental illness as documented in the registry
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Interventions

  • OtherInterviews

    * Questionnaires/Survey Measures * Qualitative Instruments

06

What researchers measure

Primary outcomes

  1. Questionnaires/Survey Measures

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → Mar 2028, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Aug 26, 2025
StartActual
Aug 15, 2025
Primary completionEst.
Mar 31, 2028was Mar 2026
CompletionEst.
Mar 31, 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 31, 2026→Mar 31, 2028
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary completion Mar 31, 2026→Mar 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07142005
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Aug 15, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Elizabeth Grubbs, MD
Contact
eggrubbs@mdanderson.org
713-792-0665
Elizabeth Grubbs, MD
principal investigator · eggrubbs@mdanderson.org

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion